Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of neurodegenerative and genetic disorders
3.2.1.2 Growing investments in research related to gene expression and delivery technologies
3.2.1.3 Growth in regulatory approvals for RNAi and antisense therapeutics
3.2.1.4 Rising awareness towards RNA-based therapeutics
3.2.2 Industry pitfalls & challenges
3.2.2.1 Requirement for significant investments in clinical studies
3.2.2.2 High cost of RNA-based therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Technology, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 RNA interference
5.3 Antisense RNA
Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Intravenous injections
6.3 Intrathecal injections
6.4 Subcutaneous injections
6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Cardiometabolic & renal disorders
7.3 Cancer
7.4 Neurodegenerative disorders
7.5 Genetic disorders
7.6 Infectious diseases
7.7 Ophthalmic diseases
7.8 Skin diseases
7.9 Other applications
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Alnylam Pharmaceuticals, Inc.
9.2 Arbutus Biopharma
9.3 Arrowhead Pharmaceuticals, Inc.
9.4 Benitec Biopharma Inc.
9.5 BioNTech SE.
9.6 CRISPR Therapeutics
9.7 GlaxoSmithKline plc
9.8 Ionis Pharmaceuticals, Inc.
9.9 Novartis AG
9.10 OliX Pharmaceuticals, Inc.
9.11 Orna Therapeutics, Inc.
9.12 Percheron Therapeutics Ltd.
9.13 Sanofi
9.14 Sarepta Therapeutics, Inc.
9.15 Silence Therapeutics
